Axon Enterprise
Axon Enterprise's revenue rose 33.5% to $2.8 billion in fiscal 2025. Its operating margin was −2.2%, down from 2.8% a year earlier. Free cash flow was $75 million, down 77.2%. The diluted share count rose 4.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What Axon Enterprise does
Axon sells technology to police, other public safety agencies and some private customers. It describes itself as a company that sells both hardware and software that work together. Its products include TASER stun devices, body cameras, in-car and fixed cameras, drones, and cloud software for storing and sharing video evidence, writing reports and running real-time operations. Many of its software tools use artificial intelligence.
It reports two segments. Software and Services sells cloud subscriptions, such as Axon Evidence, Axon Records and the Draft One report-writing tool, along with professional services and some on-premise software licenses. Connected Devices sells TASER devices, body and other cameras, drone and counter-drone products, accessories and extended warranties. Its revenue comes from hardware sales, multi-year software subscriptions, professional services and extended warranties.
Axon is based in Scottsdale, Arizona, and is expanding in Europe, Asia and the Americas. Its largest customers are law enforcement agencies, so its sales depend on their budgets and their acceptance of its products.
Its biggest risks, as it describes them
- Depending on law enforcement agencies around the world to keep buying its products and services.
- Depending on sales of its TASER devices, which may lose acceptance.
- Selling cycles are long and it spends money before it knows whether a sale will follow.
- A security breach at Axon or its cloud providers, which hold sensitive evidence.
- Uncertainty over how AI in its products will be developed, regulated and accepted.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 18.8% a year and net income 24.5% a year, as new shares raised the share count by 54% and diluted each share's earnings.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Axon Enterprise yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Axon Enterprise's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Axon Enterprise's cash from operations minus depreciation in fiscal 2025 (free cash flow before spending to grow: capital spending was 1.6 times depreciation, which holds its free cash flow down) of $128M, net cash of −$104M at December 31, 2025 and 82 million diluted shares, from its filings. The scenarios are fitted to Axon Enterprise: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 32.8% a year, kept between 0% and 20%; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 10%: 9% for a business of moderate risk (Aerospace & Defense), plus 1 point for unsteady results (a loss in fiscal 2021); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $424.77
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Axon Enterprise's earnings per share of $2.41 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 31.6×, the middle of Axon Enterprise's own P/E today, its peers' median and its sector's median (its peers' median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 11%, 10% and 9%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $424.77
- Value at this multiple, against the last close
- —
- Axon Enterprise's P/E at the last close
- 176.3×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| Axon EnterpriseAXON | $424.77 | $2.41 | 176.3× |
| BWX TechnologiesBWXT | $131.20 | $3.86 | 34.0× |
| Curtiss-WrightCW | $476.54 | $14.52 | 32.8× |
| MoogMOG-A | $358.27 | $11.76 | 30.5× |
| Leonardo DRSDRS | $35.84 | $1.19 | 30.1× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 371 | 936 | 1,243 | 788 | 1,707 |
| Debt incl. finance leases | 0 | 674 | 677 | 680 | 1,811 |
| Net debt (negative means net cash) | −371 | −262 | −565 | −108 | 104 |
| Net debt to EBITDA | — | −2.2x | −3.2x | −1.0x | 4.9x |
| Debt to equity | 0.0x | 0.5x | 0.4x | 0.3x | 0.6x |
| Interest coverage | — | — | 22.4x | 8.2x | −0.7x |
| Current ratio | 2.6x | 3.0x | 3.1x | 1.4x | 2.5x |
| Quick ratio | 2.4x | 2.7x | 2.8x | 1.2x | 2.3x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Axon Enterprise shares on the open market, and 11 insiders sold $129.6 million, $81.3 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Isaiah FieldsChief Legal Officer | Sold plan | 1,017 | $480.45 | $488,618 | Form 4 |
| Sep 8, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $508.99 | $5.1 million | Form 4 |
| Aug 31, 2026 | Joshua IsnerPresident | Sold plan | 16,775 | $574.43 | $9.6 million | Form 4 |
| Aug 21, 2026 | Jeffrey C KuninsCpo & CTO | Sold plan | 9,605 | $626.70 | $6.0 million | Form 4 |
| Aug 7, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 9,930 | $548.77 | $5.4 million | Form 4 |
| Aug 7, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 70 | $566.62 | $39,663 | Form 4 |
| Jul 7, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $643.79 | $6.4 million | Form 4 |
| Jun 29, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 10,000 | $500.00 | $5.0 million | Form 4 |
| Jun 5, 2026 | Joshua IsnerPresident | Sold | 13,000 | $488.45 | $6.3 million | Form 4 |
| Jun 4, 2026 | Patrick W SmithChief Executive Officer, Director | Sold plan | 20,000 | $500.00 | $10.0 million | Form 4 |
| Jun 4, 2026 | Elizabeth Reid CoughlinChief Human Officer | Sold | 1,554 | $485.00 | $753,690 | Form 4 |
| Jun 4, 2026 | Cameron BrooksChief Revenue Officer | Sold plan | 1,242 | $500.00 | $621,000 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 6 of 9 | 6 of 9 | 6 of 9 |
| Accruals ratio | −0.4% | −0.8% | −1.5% |
Compare
Put Axon Enterprise side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Axon Enterprise | FY25 | 33.5% | −2.2% | 2.7% | −2.2% | 4.9x | 6 | |
| BWX Technologies | FY25 | 18.3% | 12.7% | 9.2% | 13.9% | 3.0x | 7 | Compare |
| Curtiss-Wright | FY25 | 12.1% | 18.1% | 15.8% | 15.9% | 0.8x | 8 | Compare |
| Leonardo DRS | FY25 | 12.8% | 9.5% | 6.2% | 11.6% | −0.4x | 7 | Compare |
| Moog | FY25 | 7.0% | 11.7% | 3.3% | 11.7% | 1.8x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 268 | 344 | 420 | 531 | 681 | 863 | 1,187 | 1,561 | 2,082 | 2,780 |
| Revenue growth | 35.5% | 28.2% | 22.2% | 26.4% | 28.3% | 26.8% | 37.5% | 31.5% | 33.4% | 33.5% |
| Gross profit | 170 | 207 | 259 | 307 | 416 | 541 | 726 | 956 | 1,241 | 1,658 |
| Research and development | 31 | 55 | 77 | 101 | 123 | 194 | 234 | 304 | 442 | 684 |
| Operating income | 32 | 13 | 25 | −6 | −14 | −168 | 93 | 157 | 58 | −62 |
| Net income | 17 | 5 | 29 | 1 | −2 | −60 | 147 | 176 | 377 | 125 |
| Diluted EPS (US$) | 0.32 | 0.10 | 0.50 | 0.01 | −0.03 | −0.91 | 2.03 | 2.33 | 4.80 | 1.51 |
| Diluted shares (millions) | 54 | 54 | 58 | 60 | 62 | 66 | 72 | 76 | 79 | 82 |
| Cash flow | ||||||||||
| Cash from operations | 21 | 18 | 64 | 66 | 38 | 124 | 235 | 189 | 408 | 211 |
| Capital expenditure | 5 | 10 | 11 | 16 | 73 | 50 | 56 | 60 | 79 | 136 |
| Free cash flow | 16 | 8 | 53 | 50 | −34 | 75 | 180 | 130 | 330 | 75 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 4 | 11 | 5 | 0 | 0 | 22 | 2 | 21 | 622 | 647 |
| Stock-based compensation | 9 | 16 | 22 | 78 | 134 | 303 | 106 | 131 | 383 | 634 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 89 | 82 | 350 | 351 | 562 | 371 | 936 | 1,243 | 788 | 1,707 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 | 0 | 674 | 677 | 680 | 1,811 |
| Total assets | 278 | 338 | 720 | 846 | 1,381 | 1,688 | 2,852 | 3,409 | 4,475 | 7,000 |
| Total liabilities | 127 | 171 | 252 | 302 | 405 | 640 | 1,583 | 1,793 | 2,147 | 3,758 |
| Shareholders' equity | 151 | 167 | 467 | 544 | 976 | 1,050 | 1,271 | 1,616 | 2,328 | 3,243 |
| Margins and ratios | ||||||||||
| Gross margin | 63.6% | 60.2% | 61.6% | 57.9% | 61.1% | 62.6% | 61.2% | 61.2% | 59.6% | 59.6% |
| Operating margin | 11.9% | 3.8% | 5.9% | −1.2% | −2.1% | −19.5% | 7.8% | 10.1% | 2.8% | −2.2% |
| Net margin | 6.5% | 1.5% | 7.0% | 0.2% | −0.2% | −7.0% | 12.4% | 11.3% | 18.1% | 4.5% |
| Free cash flow margin | 6.0% | 2.3% | 12.6% | 9.4% | −5.0% | 8.6% | 15.1% | 8.3% | 15.8% | 2.7% |
| Return on capital | 32.1% | 8.8% | 24.4% | −2.1% | −3.7% | −24.3% | 8.2% | 15.2% | 3.5% | −2.2% |
| Return on equity | 11.2% | 3.3% | 9.2% | 0.2% | −0.2% | −5.9% | 12.7% | 12.2% | 19.1% | 4.5% |
| Return on assets | 6.8% | 1.7% | 5.5% | 0.1% | −0.1% | −3.9% | 6.5% | 5.6% | 9.6% | 2.2% |
| Net debt to EBITDA | −2.5x | −3.9x | −9.9x | −70.6x | — | — | −2.2x | −3.2x | −1.0x | 4.9x |